COST-EFFECTIVENESS ANALYSIS OF PERTUZUMAB WITH TRASTUZUMAB AND CHEMOTHERAPY COMPARED TO TRASTUZUMAB AND CHEMOTHERAPY IN THE ADJUVANT TREATMENT FOR PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER AT HIGH RISK OF RECURRENCE IN CHINA
机构：[1]China Pharmaceut Univ, Nanjing, Jiangsu, Peoples R China[2]Guangdong Tradit Chinese Med Hosp, Guangzhou, Guangdong, Peoples R China广东省中医院[3]Tianjin Med Univ Canc Hosp, Tianjin, Peoples R China[4]Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China[5]Shandong Canc Hosp, Jinan, Shandong, Peoples R China[6]Shanghai Roche Pharmaceut Ltd, Shanghai, Peoples R China[7]Shanghai Roche Pharmaceut Ltd, Beijing 11, Peoples R China
出处：
ISSN：
语种：
外文
WOS：
中科院(CAS)分区：
出版当年[2018]版：
大类|2 区医学
小类|2 区卫生保健与服务
最新[2025]版：
大类|2 区医学
小类|2 区卫生保健与服务2 区卫生政策与服务3 区经济学
JCR分区：
出版当年[2017]版：
Q1HEALTH CARE SCIENCES & SERVICESQ1ECONOMICSQ1HEALTH POLICY & SERVICES
最新[2023]版：
Q1ECONOMICSQ1HEALTH CARE SCIENCES & SERVICESQ1HEALTH POLICY & SERVICES
第一作者机构：[1]China Pharmaceut Univ, Nanjing, Jiangsu, Peoples R China
推荐引用方式(GB/T 7714)：
Guan X.,Li H.,Chen Q.,et al.COST-EFFECTIVENESS ANALYSIS OF PERTUZUMAB WITH TRASTUZUMAB AND CHEMOTHERAPY COMPARED TO TRASTUZUMAB AND CHEMOTHERAPY IN THE ADJUVANT TREATMENT FOR PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER AT HIGH RISK OF RECURRENCE IN CHINA[J].VALUE IN HEALTH.2019,22:S405-S406.
APA：
Guan, X.,Li, H.,Chen, Q.,Hao, C.,Li, J....&Ma, A..(2019).COST-EFFECTIVENESS ANALYSIS OF PERTUZUMAB WITH TRASTUZUMAB AND CHEMOTHERAPY COMPARED TO TRASTUZUMAB AND CHEMOTHERAPY IN THE ADJUVANT TREATMENT FOR PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER AT HIGH RISK OF RECURRENCE IN CHINA.VALUE IN HEALTH,22,
MLA：
Guan, X.,et al."COST-EFFECTIVENESS ANALYSIS OF PERTUZUMAB WITH TRASTUZUMAB AND CHEMOTHERAPY COMPARED TO TRASTUZUMAB AND CHEMOTHERAPY IN THE ADJUVANT TREATMENT FOR PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER AT HIGH RISK OF RECURRENCE IN CHINA".VALUE IN HEALTH 22.(2019):S405-S406
